Evidence for the use of pharmacotherapies for vaping cessation is limited. Most pharmacotherapies that are TGA approved for smoking cessation are not approved for vaping cessation.
A faster-acting nicotine replacement therapy (NRT) product (mouth spray) has recently been approved by the Therapeutic Goods Administration (TGA) as the first NRT aid for the treatment of tobacco and nicotine vaping dependence by relieving nicotine withdrawal symptoms from smoking and vaping, thereby facilitating cessation in people who smoke or vape and are motivated to quit.
For people who smoke or vape who are currently unable or not ready to stop smoking and vaping abruptly, the mouth spray may also be used as part of a reduction strategy as a step towards stopping completely.
For guidance on vaping cessation support see:
Guideline: RACGP Supporting smoking & vaping cessation: A guide for health professionals (PDF)
Guideline: PSA Professional practice guidelines – nicotine dependence support (PDF)